FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Biopharma execs sign on to tout UK's R&D work

Tools

A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Chris Brinsmead, president of AstraZeneca U.K., will chair a 12-man strategy group for UK Trade & Investment to scout overseas markets for the U.K.'s life sciences industry while recruiting overseas investors. The life sciences industry is one of five sectors getting some muscular promotional support. And with the largest pipeline for new products in Europe, the country feels it has plenty to boast about.

"The UK is Europe's top location for research and development and a global hub for scientific research, but retaining this position in the face of growing competition from abroad is a significant challenge," Lord Digby Jones, the UK's trade minister, told The Times.

- read the report from The Times

Related Articles:
Market volatility spurs M&A talks at UK biotechs. Report
U.K. to require more disclosure of drug trial data. Report
U.K. researchers driven out by tough regulations. Report
GSK looks abroad for more scientists as U.K. shortage grows. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about AstraZeneca   GlaxoSmithKline   Europe   pipeline   United Kingdom   Chris Brinsmead  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.